STAT

JANUARY 31, 2024

Overall, Novo saw 154% growth in obesity drug revenue in 2023, driven by sales of its older obesity drug Saxenda and the launch of Wegovy in additional countries. In response to concerns over multi-million-dollar price tags for new gene therapies for sickle cell disease, the U.S.

105

105

The Checkup by Singlecare

DECEMBER 5, 2023

The #ozempic tag on TikTok has amassed over 1 billion views to date. Saxenda (liraglutide): Another GLP-1 weight management drug, Saxenda is a medication that many use as an alternative to Ozempic or Wegovy. Studies have shown that Saxenda is less effective than Wegovy for weight loss.

Insurance 105

Insurance Prescription Filling FDA Dosage 105

The Checkup by Singlecare

NOVEMBER 2, 2023

As a result, there is a greater demand for GLP-1 drugs like Wegovy (semaglutide) , Saxenda (liraglutide) , and Mounjaro (tirzepatide). Currently, the only GLP-1s that are FDA approved for chronic weight management in people without diabetes are Wegovy (semaglutide) and Saxenda (liraglutide)—as long as patients meet certain criteria.

Insurance 52

Insurance FDA Adverse Reactions Hospitals 52

The Checkup by Singlecare

SEPTEMBER 7, 2023

Other GLP-1 receptor agonists (with indication for diabetes) If the price of Mounjaro or insurance coverage is not sustainable, the first move might be to find a GLP-1 drug with a lower price tag or better coverage on an insurance plan. All GLP-1 agonists today are injectable drugs except for Rybelsus, the only oral option.

Insurance 52

Insurance Insurance Coverage FDA Dosage 52

Pharmaceutical Technology

NOVEMBER 30, 2022

The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. weight loss in obese or overweight individuals. Novo Nordisk is another company leading the charge in this field.

Insurance 105

Insurance Labelling Communication FDA 105

Pharmaceutical Technology

NOVEMBER 30, 2022

The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. weight loss in obese or overweight individuals. Novo Nordisk is another company leading the charge in this field.

Insurance 98

Insurance Labelling Communication FDA 98